Several FRET (fluorescence resonance energy transfer)-based biosensors for intracellular detection of cyclic nucleotides have been designed in the past decade. However, few such biosensors are available for cGMP, and even fewer that detect low nanomolar cGMP concentrations. Our aim was to develop a FRET-based cGMP biosensor with high affinity for cGMP as a tool for intracellular signaling studies. We used the carboxyl-terminal cyclic nucleotide binding domain of Plasmodium falciparum cGMP-dependent protein kinase (PKG) flanked by different FRET pairs to generate two cGMP biosensors (Yellow PfPKG and Red PfPKG). Here, we report that these cGMP biosensors display high affinity for cGMP (EC50 of 23 ± 3 nM) and detect cGMP produced through soluble guanylyl cyclase and guanylyl cyclase A in stellate ganglion neurons and guanylyl cyclase B in cardiomyocytes. These biosensors are therefore optimal tools for real-time measurements of low concentrations of cGMP in living cells.
Cyclic guanosine 3′,5′-monophosphate (cGMP) is a second messenger involved in several intracellular signaling pathways in a variety of physiological functions and neurological and cardiovascular pathophysiology. Cyclic GMP is synthesized by NO-dependent activation of soluble guanylyl cyclase (sGC) and natriuretic peptide (NP)-dependent activation of particulate guanylyl cyclases; it activates protein kinase G (PKG) and cyclic nucleotide (CN)-gated ion channels and regulates phosphodiesterases (PDEs). The produced cGMP is degraded by PDEs. Cyclic GMP levels can be elevated by nitric oxide donors, sGC activators and stimulators, NPs and inhibition of specific PDEs, and several of these strategies protect the heart from pathological remodeling and ameliorate pulmonary arterial hypertension1,2,3,4,5.
To investigate CN content, widely used methods to quantify CN production and degradation measures total intracellular content after cell lysis. However, this prevents measurement of the rapid dynamics and spatial intracellular organization of cGMP production and degradation. During the last decade, FRET (fluorescence/Förster resonance energy transfer) has been widely used to measure either protein–protein interactions or protein conformational changes through use of fluorescent biosensors. Such biosensors can be applied to detect CNs and consist of a CN-binding domain (BD), flanked by two fluorescent molecules. Upon CN-binding, the BD alters its protein conformation, thus changing the distance and increasing or decreasing FRET between the fluorophores6,7. Using such FRET-based biosensors, one can measure intracellular CN concentrations in real-time in single cells and overcome the limitations of traditional methods. Biosensors can either freely diffuse throughout the cell or be targeted to subcellular microdomains by tagging biosensors with specific proteins or short peptide sequences7,8,9.
The dynamic measurement of intracellular cAMP concentrations has been successfully achieved by several intracellular FRET-based biosensors7,8,10. In contrast, dynamic measurements of intracellular cGMP have been challenging due to a paucity of FRET-based biosensors with high enough affinity for cGMP. Currently, the most frequently used biosensors for cGMP consist of a mammalian cGMP BD flanked by the fluorophores CFP and variants of YFP: Cygnet 2.1 (tandem CN BD and catalytic domains from PKG I with EC50 ~1.7 μM)11, cGi-500, cGi-3000 (only the tandem CN BD from PKG I with EC50 ~0.5 µM and 3 µM, respectively)12 and the cGES-DE5 (GAF (mammalian cGMP-binding PDEs, Anabaena adenylyl cyclases, and E. coli FhlA) domain of PDE5 with EC50 ~1.5 μM)13. These biosensors with µM affinity have been used in cells where cGMP concentrations are relatively high, e.g. rat neonatal cardiomyocytes14, smooth muscle cells15 and mouse oocytes16. However, these biosensors have severe limitations in cells with low cGMP concentrations, which include adult cardiomyocytes and stellate ganglion (SG) neurons17,18 where more sensitive biosensors are needed. For the cGES-DE5-based biosensor, exchange of fluorophores to T-sapphire and Dimer2 (Red cGES-DE5) increased the affinity for cGMP by ~35 fold19, making it the only biosensor with high enough affinity to detect cGMP in cells with low cGMP, such as adult cardiomyocytes17.
The protozoan parasite Plasmodium falciparum (Pf) is the cause of the most severe form of malaria20. Malaria transmission requires the gametogenesis phase within a mosquito. Although the signaling events that regulate the gametogenesis are not fully understood, cGMP is involved in promoting the gametocyte differentiation by activation of PfPKG21,22. PfPKG contains an N-terminal regulatory and a C-terminal catalytic domain displaying approximately 30–33% similarity with the mammalian PKGs. The most notable difference, compared with the mammalian PKGs, is the presence of four PfPKG cGMP-BDs in the regulatory domain22,23,24, compared to only two in mammalian PKGs. Moreover, the fourth cGMP BD (D-domain) displays high affinity (~40 nM) and selectivity for cGMP and serves as a gatekeeper domain for cGMP-dependent activation25. Recently, the apo- and cGMP-bound structures of the D-domain of PfPKG were determined at high resolution25. Based on these structures, we constructed a FRET-based cGMP biosensor by flanking the PfPKG D-domain with fluorescent protein pairs. We find that these biosensors display high affinity for cGMP and therefore could be utilized in cells with inherent low cGMP concentrations, such as cardiomyocytes and SG neurons.
Development of high affinity FRET-based cGMP biosensors
To design a high affinity cGMP biosensor, we analyzed the structure of the CN-binding domain D of PfPKG (Fig. 1a, b) and found that the distance between the N- and C-termini (S403 and E542) was 35 Å in the absence of cGMP and increases to 56 Å upon cGMP binding (Fig. 1b). We therefore constructed a FRET-based biosensor by adding the fluorophores CFP and Venus (a YFP-variant) to the N- and C-terminus of the PfPKG D-domain, respectively, and termed it Yellow PfPKG (Fig. 1a). Next, we determined whether cGMP-binding altered FRET by expressing the biosensor in HEK293 cells and incubated homogenates with increasing concentrations of cGMP. Cyclic GMP decreased FRET (increased CFP/Venus ratio) in a concentration-dependent manner (Fig. 1c, d), suggesting that the N- and C-termini move further apart upon cGMP-binding. The affinity was in the nanomolar range (EC50 of 22.5 ± 2.8 nM) and the maximal change in FRET at the highest cGMP concentration was 39.4 ± 3.5% (Fig. 1g, Table 1). To exclude whether basal cGMP from HEK293 cells interfered with our measurements, we constructed and purified a His-tagged Yellow PfPKG biosensor and found a similar affinity for cGMP (30 ± 2 nM; Supplementary Fig. 1) and maximal change in FRET (42.3 ± 0.4%). This indicates that the potential influence of endogenous cGMP from HEK293 cells on the determined cGMP affinity of our biosensor is negligible.
For the cGES-DE5 cGMP biosensor13, replacing the CFP/YFP FRET pairs with T-sapphire/Dimer2 increased the affinity for cGMP by almost 40-fold19. To determine whether replacing the FRET pair of our Yellow PfPKG biosensor could modify cGMP affinity, we constructed the Red PfPKG biosensor, where CFP and Venus were replaced with T-sapphire and Dimer2 (Fig. 1a). The Red PfPKG biosensor displayed similar affinity for cGMP (EC50 30.7 ± 9.3 nM) as the Yellow PfPKG, but with a lower dynamic range (27.9 ± 2.7% of the FRET change seen with the Yellow PfPKG; Fig. 1e–g, Table 1). These results show that replacing the fluorophores does not necessarily change the binding affinity since the EC50 was unchanged and secondly, that the T-sapphire and Dimer2 FRET pair produced a response with a lower dynamic range compared to the CFP/Venus FRET pair.
In the FRET-based cAMP biosensor based on EPAC1, replacing the acceptor (Venus) with a tandem Cp173Venus-Venus increased the energy transfer efficiency and thus the dynamic range26. Therefore, to further improve the dynamic range of our Yellow PfPKG biosensor, we replaced Venus with Cp173Venus-Venus. We found a reduction in the dynamic range (>60% reduction; Table 1) and a possible reduction in cGMP affinity (46.5 ± 6.6 nM; p = 0.13). Thus, simply adding a tandem Cp173Venus-Venus to any biosensor does not enhance the magnitude of the FRET response.
Real-time cGMP monitoring in single cells
To determine if the Yellow and Red PfPKG are functional in living cells, we first expressed the biosensors in HEK293 cells. As shown in Fig. 2a, b, each fluorophore is expressed in HEK293 cells and diffusely, although not homogeneously, located throughout the cytoplasm. Thereafter, we monitored in real-time the cGMP produced in single cells through activation of sGC. Stimulating cells with the NO-donor SNAP (50 nM) increased FRET by 14.4 ± 1.1% for the Yellow PfPKG biosensor and 21.8 ± 4.5% for the Red PfPKG biosensor (Fig. 2c, d). Inhibiting PDE degradation of cGMP with the non-selective PDE inhibitor IBMX (100 µM) further increased the FRET by 8.9 ± 6.9% for the Yellow PfPKG biosensor and 5.2 ± 2.4% for the Red PfPKG biosensor. Comparing the two biosensors, we found that the Yellow PfPKG displayed a significantly larger dynamic range in intact HEK293 cells compared to the Red PfPKG (41.5 ± 6.8% vs. 23.4 ± 2.6% maximal FRET change, respectively; p = 0.0002; Fig. 2e). We also measured total cellular cGMP and found that a higher concentration of SNAP (100 µM) was required to elicit a response and that CNP did not increase cGMP in HEK293 cells (Fig. 2f).
To determine whether our biosensors can detect low cGMP concentrations, we expressed the Yellow PfPKG in cardiomyocytes where maximal cGMP concentrations are in the low nanomolar range17. To express Yellow PfPKG in adult rat ventricular cardiomyocytes, we transduced cardiomyocytes with the biosensor using adenovirus (Fig. 3a). In contrast to the results obtained with HEK293 cells, stimulation of cardiomyocytes with a high concentration of SNAP (100 µM) did not alter FRET (Fig. 3b), despite increasing intracellular NO release (Supplementary Fig. 2). To exclude the possibility that constitutive sGC activation (or endogenous NO production) increases cGMP to concentrations that would saturate the biosensor, we incubated cells with an inhibitor of sGC (10 µM ODQ). ODQ did not modify FRET (Fig. 3c), suggesting that cGMP levels from activation of sGC are rather too low to be detected by the biosensor. In addition, measuring SNAP-stimulated total cGMP concentrations in cardiomyocytes only revealed a small pool of cGMP, apparently not accessible to our biosensor (Fig. 3d).
Next, we stimulated the particulate GCs in cardiomyocytes. While GC-A stimulation with BNP (300 nM) produced a modest FRET response (2.0 ± 0.4%, Fig. 3e, j), stimulation of GC-B receptors with CNP (300 nM) increased FRET by 32.8 ± 3.4% (Fig. 3f, j), consistent with other reports17,27,28,29. Adding IBMX (100 µM) further increased FRET by 5.4 ± 1.7%. From these results, we conclude that our biosensor detects cGMP in cardiomyocytes and secondly that GC-B-stimulation triggers a greater pool of cGMP compared to GC-A and sGC activation in cardiomyocytes, in line with our previous functional data27,29,30.
Next, we compared our Yellow PfPKG with the only other cGMP biosensor reported in adult cardiomyocytes, the Red cGES-DE5 biosensor17,28. CNP-stimulation of cardiomyocytes expressing Red cGES-DE5 increased FRET by 16.5 ± 3.1% (Fig. 3g, j). However, the Red cGES-DE5 displayed a significantly (p = 0.0001) lower dynamic range; 20.8 ± 2.1% (maximal FRET change; CNP + IBMX) compared to the Yellow PfPKG (35.0 ± 2.1%, Fig. 3k). Since both the Yellow PfPKG and the Red cGES-DE5 biosensors detect cGMP with similar affinities in vitro (Table 1 and Niino et al.19), we determined their response to increasing concentrations of CNP in intact cardiomyocytes (Fig. 3h, i) and found a relatively similar potency of CNP with the two biosensors (pEC50 7.4 ± 0.2 for the Yellow PfPKG and 7.1 ± 0.1 for the Red cGES-DE5; p = 0.37). This indicates that the Yellow PfPKG biosensor has similar or slightly higher sensitivity for cGMP compared to established biosensors and yields a larger dynamic range.
Previously, we used the cGi-500 cGMP biosensor in SG neurons and observed that BNP stimulation of GC-A increased cGMP and reduced noradrenaline release18. However, cGi-500 only showed a modest signal after GC-A stimulation, suggesting low levels of cGMP. Therefore, we tested our Yellow PfPKG biosensor to better visualize the low cGMP produced by BNP stimulation. We performed real-time measurements of cGMP by expressing either the cGi-500 or the Yellow PfPKG biosensor in SG neurons. Adding increasing concentrations of BNP (10, 100, and 250 nM) increased FRET (Fig. 4a–c). The highest concentration of BNP (250 nM) increased FRET more for the Yellow PfPKG than for the cGi-500 biosensor (p = 0.01). Next, we activated sGC by applying the sGC activator BAY 41-2272 and found that both biosensors gave an increase in FRET (Fig. 4d–f). To determine the dynamic range of both biosensors in SG neurons, we saturated cGMP levels by stimulating with both the NO donor Sin-1 (20 µM) and IBMX (100 µM). The maximal FRET change observed for the cGi-500 was significantly higher (p < 0.0001) than the Yellow PfPKG biosensor (Fig. 4g).
PfPKG biosensors display 100-fold selectivity
Next, we determined the cGMP selectivity by incubating the PfPKG biosensors with increasing concentrations of cAMP and measuring FRET (Fig. 5a, b). We found that cAMP increased FRET at ~100-fold higher concentrations compared to the cGMP response (cAMP EC50 of 4.6 ± 2.1 μM and 1.9 ± 0.6 µM for the Yellow and Red PfPKG biosensors, respectively). To determine if cAMP levels in HEK293 cells were detected by the Yellow PfPKG, we stimulated endogenous β-ARs in HEK293 cells31 with isoprenaline (10 μM) and found a 3.7 ± 0.5% increase in FRET (Fig. 5c). In separate experiments, direct activation of adenylyl cyclases by forskolin (25 µM) increased FRET by 13.8 ± 2.8% (Fig. 5d). However, in both cases, further stimulation with SNAP (50 nM) gave an additional increase in FRET (11.6 ± 2.8% after isoprenaline and 29.5 ± 5.1% after forskolin), excluding the possibility that the biosensor was fully saturated (Fig. 5c, d). Together, these results suggest that the biosensor is only sensitive to high cAMP concentrations. To determine whether this was also the case in cardiomyocytes, we incubated these with isoprenaline (10 nM) and obtained a 10.9 ± 2.6% transient change in FRET. Additional stimulation with CNP (300 nM) gave a further increase of 19.4 ± 3.2% and subsequent stimulation with IBMX (100 µM) gave an additional 2.6 ± 0.7% increase in FRET (Fig. 5e, g). The Red cGES-DE5 biosensor, on the other hand, did not detect a similar cAMP increase (Fig. 5f, g).
Since this could pose a problem for measuring cGMP within the cells where cellular cAMP levels are 10–100 fold higher than the cGMP levels, we attempted to reduce the affinity towards cAMP without altering the affinity for cGMP. Previously, the Zagotta group demonstrated that mutation of an isoleucine residue to aspartic acid (Ile636Asp) in an HCN ion channel of sea urchin sperm (SpIH channel), resulted in a cGMP selective and sensitive SpIH channel32. Aligning the PfPKG D-domain with the CN-BD of the mutant SpIH channel (Ile636Asp) showed that Val536 of PfPKG is analogous to Ile636. Thus, we hypothesized that replacing Val536 with polar or charged amino acids (glutamine, glutamic acid, asparagine or aspartic acid) could improve cGMP selectivity. We therefore mutated Val536 to Gln, Glu, Asn, and Asp. Although the affinity for cGMP was retained, the selectivity did not improve, as both CN affinities were essentially unaltered (Table 1). This suggests that other molecular determinants within the PfPKG D-domain are responsible for cGMP selectivity compared to the SpIH channel.
In this paper, we developed previously unreported FRET-based biosensors that can monitor cGMP dynamics in real time in intact cells with low intrinsic cGMP levels. The Yellow PfPKG biosensor displays nanomolar affinity for cGMP and a large dynamic range. In addition, we detected GC-A- and GC-B-stimulated cGMP in cardiomyocytes and SG neurons, both examples of cells that have low cGMP concentrations.
The two biosensors described herein (Yellow and Red PfPKG) differed only in terms of their efficacy, where the Red PfPKG displayed a smaller dynamic range (Figs. 1g, 2e and Table 1). A similar reduction in dynamic range was also reported for the red vs. yellow versions of the cGES-DE5 biosensor19. This might be due to a different relative change of energy transfer upon cGMP binding in CFP/Venus compared to the T-Sapphire/Dimer2 fluorescent pairs. However, despite a lower dynamic range, the Red PfPKG could still offer other advantages: the emission spectrum of T-sapphire/Dimer2 shows a reduced overlap compared to CFP/Venus, and thus a reduced bleed-through of donor in the acceptor channel19, that increases the signal-to-noise ratio; cells have less autofluorescence at higher wavelengths33 (emission 537/623 nm vs. 470/530 nm for CFP/YFP), giving lower background noise; and longer emission wavelengths are favorable for deep-tissue imagining34,35, thus improving application of FRET imaging in tissues.
Stimulation of single HEK293 cells with 50 nM SNAP increased cGMP when using our biosensors (Fig. 2c, d). However, in experiments determining cGMP in whole cell lysates, this concentration of SNAP yielded barely detectable increases of cGMP (Fig. 2f), and higher concentration of SNAP was required to reveal a large cGMP increase in our global cGMP assay. This suggests that the PfPKG biosensors offer more sensitive tools to detect low concentrations of cGMP. Therefore, in cells where sGC-, GC-A- or GC-B-stimulated cGMP levels are low, such as cardiomyocytes17, a biosensor with high cGMP affinity could be suitable. In fact, the PfPKG biosensor detected a large increase in cGMP after activation of GC-B by CNP and a small increase in cGMP after GC-A stimulation (Fig. 3j). Similar observations were also made in mouse cardiomyocytes using the Red cGES-DE5 biosensor17,28. Comparing the Yellow PfPKG and Red cGES-DE5 biosensor, we observed similar sensitivity to CNP stimulation, consistent with similar affinities for cGMP (Table 1 and Niino et al.19), but the Yellow PfPKG biosensor displayed a larger dynamic range (Fig. 3k). The pEC50 for CNP is 7.4 ± 0.2, corresponding to an EC50 value of about 41 nM for the Yellow PfPKG biosensor (Fig. 3i) and we have previously reported that CNP induced a negative inotropic response and positive lusitropic response in rat muscle strips with a similar EC5036. Also, CNP-induced modulation of β-AR-mediated positive inotropic response through PDE3 inhibition displayed a similar EC5029. This suggests that the physiological effects of CNP are well within the cGMP concentration range detected by the Yellow PfPKG biosensor.
It is well known that NO and sGC are present in cardiomyocytes and increase cGMP37. However, the detection of NO-stimulated cGMP by FRET-based biosensors has been a challenge to others17 and despite the high cGMP affinity of the PfPKG biosensors, they could not detect any cGMP even after 100 µM SNAP (Fig. 3b). However, in our measurements of total cellular cGMP content, this concentration of SNAP resulted in a small increase of cGMP in cardiomyocytes (Fig. 3d). We therefore speculate that the cGMP produced by sGC is restricted to compartments where our biosensor cannot get access. Interestingly, the confocal images show that the PfPKG biosensor is not expressed evenly throughout the cardiomyocytes (Fig. 3a), suggesting that their expression or movement is somewhat limited. A similar non-uniform distribution pattern is also clearly seen with other non-targeted biosensors7,17,38,39,40. Perhaps such untargeted biosensors do not have access to certain intracellular structures or organelles where tight spatial signaling, such as that from sGC, could be confined.
Cardiac function can be modulated by the autonomic nervous system through a complex neuronal network. The sympathetic SG neurons innervate the sino-atrial node and myocardium and release noradrenaline that induces chronotropic and inotropic responses in the heart41. BNP released from the heart is a compensatory mechanism in conditions such as heart failure and hypertension42. We have previously shown that BNP decreases noradrenaline release, but we detected only very limited increases in cGMP by using established FRET-based biosensors18. Thus, with the PfPKG biosensor we revisited the cGMP dynamics upon stimulating SG neurons with BNP. The PfPKG biosensor successfully detected the BNP-stimulated cGMP increase with a larger change in FRET compared to the cGi-500 (Fig. 4a–c). This is consistent with the >20-fold higher affinity of PfPKG for cGMP. However, the dynamic range of the cGi-500 was larger than the PfPKG biosensor (Fig. 4g). Thus, when comparing the two biosensors as per cent of maximal response, the difference between the biosensors in detecting the BNP effect was more accentuated (Supplementary Fig. 3). The reduced dynamic range is less likely due to the fluorescent pair, as they both share the same donor (CFP) and the PfPKG contains a different acceptor (Venus) which is ~30 times as bright as the YFP43 in cGi-500. However, the fluorophores of PfPKG are attached to S403 and E542 and the distance between these is only increased by 21Å upon cGMP binding (Fig. 1b) which could account for a smaller change in FRET.
Considering the structural similarity between cGMP and cAMP and that increasing cGMP might inhibit PDE3-mediated degradation of cAMP44, it is important to determine the selectivity of our biosensor. In vitro measurements show a selectivity of 100-fold for cGMP over cAMP and this is in accordance with the previous EC50 values seen in the isolated D-domain using fluorescence polarization assays25. In live single cell measurements, stimulation of cAMP production resulted in a small response of the PfPKG biosensor in both HEK293 cells and cardiomyocytes (Fig. 5). However, the biosensor was not saturated, as we could obtain a further change in FRET after stimulation of sGC (HEK293 cells) or GC-B (cardiomyocytes), suggesting that high concentrations of cAMP may elicit a modest response. Given that the Km of PDE3 for cGMP and cAMP is 0.1–0.8 µM45, cGMP would start to inhibit PDE3 at concentrations where our biosensor is saturated. Additionally, the EC50 of CNP was similar between the PfPKG and the cGMP-selective Red cGES-DE5 biosensor. Taken together, the potential increases in cAMP levels by cGMP-mediated PDE3 inhibition will not be detected by the PfPKG biosensor. However, in experiments where both cGMP and cAMP levels are simultaneously elevated46, the PfPKG biosensor alone cannot discriminate between low levels of cGMP and high levels of cAMP. To control for this, the Yellow PfPKG biosensor would be suitable to use in combination with a cAMP biosensor, such as the Pink Flamindo47, a single fluorophore biosensor with excitation (567 nm) and emission (590 nm) that do not interfere with the Yellow PfPKG emission spectrum.
To conclude, we have generated two previously unreported biosensors for cGMP with high affinity and one of these display a large dynamic range. The biosensors contain the same BD for cGMP but with different fluorophores and could therefore be applied for multiparameter fluorescence imaging which requires the simultaneous combination of different FRET biosensors.
S-Nitroso-N-acetyl-DL-penicillamine (SNAP) and 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) were from Tocris Bioscience (Bristol, UK); 4-Amino-5-methylamino- 2',7'-difluorofluorescein diacetate (DAF-FM-DA) was from abcam (Cambridge, UK); human C-Type Natriuretic Peptide (CNP) and rat Brain Natriuretic Peptide (BNP) were from GenScript Corp. (Piscataway, NJ,USA); All other chemicals and media were from Sigma-Aldrich (Sigma-Aldrich, St.Louis, MO), unless otherwise noted.
Generating PfPKG biosensors
The sequence encoding Yellow PfPKG (PfPKG D domain S403-E542, flanked by CFP and Venus) and the CFP/Cp173Venus-Venus biosensor variant (PfPKG D domain S403-E542 flanked by CFP and Cp173Venus-Venus), synthesized by Genscript, were moved into pcDNA3.1(-). The Yellow PfPKG biosensor was then packaged in adenovirus type 5, amplified and titer measured by VectorBiolabs (Malvern, PA). To obtain the Red PfPKG biosensor, the PfPKG D-domain sequence (S403-E542) was synthetized flanked by SphI/SacI restriction sequences and inserted into SphI/SacI-opened pUC57 vector by Genscript. The two fluorophores were ligated by inserting XhoI/SphI-cut T-sapphireΔC11 (T-sapphire)48 fragment N-terminally and EcoRI/SacI-cut Dimer249 fragment C-terminally into SphI/SacI-opened PfPKG. Dimer2 (evolved from DsRed) is thus transcribed as a monomer, but has been shown to associate into a dimer49. Both fluorophores were excised from a Red cGES DE5 biosensor plasmid (synthesized by Genscript). The correct sequence was then moved into the expression vector pcDNA3.1(-). The Red cGES DE5 biosensor was packaged in adenovirus type 5, amplified and titer measured by VectorBiolabs (Malvern, PA).
Constructing the His-TEV-Yellow PfPKG biosensor
A His-7-TEV N-terminal tag was amplified from pQTEV (Addgene #31291) using forward and reverse primers (GGAGACCCAAGCTGGCTAGCATGAAACATCACCATCACCATC and CACAGGTACCGCAAGCTCGAATCCCTGAAAATAAAGATTCTC, respectively) and inserted N-terminally into a NheI- and XhoI-opened Yellow PfPKG vector using In-Fusion HD Cloning Kit (Takara Bio, Mountain View, USA,Inc.) according to the manufacturer’s protocol.
Point mutations in the PfPKG Red biosensor were performed using QuikChange II Site-Directed Mutagenesis Kit (Agilent technologies, Santa Clara, California, USA) according to the manufacturer’s protocol.
Transfection of HEK293 cells and in vitro FRET assay
HEK293 cells (ATCC) were cultured in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 µg/ml) (ThermoFischer, Waltham, Massachusetts, USA). Cells were transiently transfected with the indicated plasmids using LipofectAMINE 2000 (ThermoFischer) according to the manufacturer’s protocol. After transfection, cells were either cultured on poly-lysin-coated glass cover-slides for FRET and confocal imaging (below) or cultured for 48 h for the in vitro FRET assay, then homogenized with Ultra-Turrax (Franke & Kunkel KG, Staufen, Germany) for 30 s at 4 °C in Buffer A (HEPES 10 mM pH 7.3, NaCl 137 mM, KCl 5.4 mM, CaCl2 2 mM, MgCl2 1 mM). Homogenates were stimulated with increasing concentrations of cGMP or cAMP in the presence of 100 µM IBMX. The donor fluorophore CFP was excited at 430 nm (430/24 filter), T-Sapphire was excited at 405 nm, (405/8 filter) and the fluorescence emission (F) of Venus and CFP (535/25 nm and 470/24 nm, respectively) or Dimer2 and T-Sapphire (590/20 nm and 515/30 nm, respectively) were measured on an EnVision plate reader (PerkinElmer, Melville, NY, USA). To visualize a positive response to cGMP, the FRET response was calculated as changes in FCFP/FVenus and FT-Sapphire/FDimer2. Emission spectra of the biosensors in homogenates were measured on a Synergy H1 plate reader (BioTek Instruments, Winooski, VT, USA) through excitation of both biosensors at 405 nm and recording emission from 450 to 670 nm.
Purification of Yellow PfPKG biosensor
His-TEV-Yellow PfPKG biosensor was purified using a 5 ml HisTrap HP column supplied with Ni2+ ions (GE Healthcare, UK) coupled to a workstation and a BioLogic recorder (BIO-RAD). Prior to use, the column was pre-equilibrated with phosphate buffered saline with 0.05% sodium azide (PBS/0.05% sodium azide). Homogenate of HEK293 cells expressing the His-TEV-Yellow PfPKG biosensor was centrifuged at 4000 rpm for 40 min and the supernatant filtered with a 0.22 µm filter. This was applied to the HisTrap column with a flow of 0.5 ml/min, followed by washing using 150 ml of PBS/0.05% sodium azide and 50 ml of 25 mM Imidazole/PBS. The bound biosensors were eluted with 50 ml 250 mM imidazole/PBS (pH 7.3). The proteins were up-concentrated and buffer changed to Buffer A using Amicron Ultra-30 columns (Millipore).
Animal care was according to the Norwegian Animal Welfare Act (and approved by the Norwegian Animal Research Authority) and Use of Laboratory Animals (publication no. 85-23, revised 1996) and Animals (Scientific Procedures) Act 1986 (United Kingdom) which both conform to the European Convention for the protection of Vertebrate animals used for Experimental and other Scientific Purposes (Council of Europe no. 123, Strasbourg 1985).
Isolation of cardiomyocytes
Primary culture and transduction of cardiac ventricular myocytes from male Wistar rats were prepared27, attached to laminin-coated cover slides and transduced with adenovirus containing the biosensor as previously described50,51.
Isolation of stellate ganglion neurons
Three- to four-week old male Wistar rats were sacrificed by an approved Home Office Schedule 1 method comprising (under isoflurane anesthesia) intraperitoneal pentobarbitone overdose (500 mg/kg) followed by exsanguination. Both stellate ganglia were excised intact and placed into Ca2+- and Mg2+-free Hanks’ Balanced Salt Solution on ice, where any contaminating tissue was dissected away before they were each cut into 6–8 pieces. These next underwent enzymatic digestion in collagenase IV (22 min) and trypsin (25 min) at 37 °C, before two 5 min incubations in blocking buffer (87.12% Leibovitz’s L-15 medium, 0.54% D-(+)-glucose solution, 1.8 mM L-glutamine, 90 units/ml penicillin, 90 μg/ml streptomycin and 10% fetal bovine serum). Finally the ganglionic tissue was mechanically triturated in neuronal plating medium (90% L-15 medium, 24 mM NaHCO3, 38 mM glucose, 50 units/ml penicillin, 50 μg/ml streptomycin, 50 μM NGF and 10% foetal bovine serum) using a glass Pasteur pipette with a fire-polished tip to produce a single cell suspension, which was seeded onto 6 mm poly-D-lysine/laminin coated glass coverslips. These were kept at 37 °C under 5% CO2 in neuronal plating medium.
Twenty four to forty eight hours after HEK293 transfection or cardiomyocyte transduction, cells were incubated in Buffer B (NaCl 144 mM, KCl 1.97 mM, CaCl2 1 mM, MgCl2 1 mM, KH2PO4 0.43 mM, K2HPO4 1.5 M, glucose 10 mM) and visualized under an Olympus FV1000/BX61 confocal microscope using a water immersion objective (×60 1.1 NA). Cells were sequentially excited with a 458 nm laser for CFP and 515 nm laser for Venus, 488 nm laser for T-sapphire and 543 nm laser for Dimer2 and the emission was measured by Olympus Fluoview 1000 at 475/25 nm and 527/100 nm, for CFP and Venus, respectively, and at 510/30 nm and 581/100 nm for T-sapphire and Dimer2, respectively.
Twenty four to forty eight hours after HEK293 transfection or cardiomyocyte transduction, cells were placed into a watertight cell imaging chamber (Attofluor, ThermoFischer) at room temperature in Buffer A (HEK293 cells) or Buffer B (cardiomyocytes). Cells expressing the biosensors were visualized through a motorized digital inverted fluorescent microscope (iMIC; FEI, Graefelfing, Germany) with an oil objective (×60 1.35 NA for HEK293 cells and ×40 1.35 NA for cardiomyocytes; Olympus, Tokyo, Japan). Fluorescent molecules were illuminated by a monochromator with fast-switching wavelengths (Polychrome V; FEI) for 20–80 ms at a frequency of 0.1–1 Hz. Cells expressing the red biosensors were excited for 80 ms at 422 ± 15 nm and 572 ± 15 nm consecutively and emission from T-sapphire and Dimer 2 were separated using a dichrotome iMIC Dual Emission Module, where a 560LP filter separates the two fluorophores’ images on a single EM-CCD camera chip (EVOLVE 512; Photometrix, Tucson, USA). Fluorescence, from excitation at 422 nm, was measured at 537 ± 29 nm for T-sapphire and at 623 ± 25 nm for Dimer2 emission. FRET was measured as ratios of T-sapphire over Dimer2 (T-sapphire/Dimer2 ratio). Dimer2 emission was corrected for spillover of T-sapphire emission into the Dimer2-channel (15.1%). Cells expressing the yellow biosensor were excited at 436 ± 10 nm for 20–80 ms and emission was split using a dichrotome iMIC Dual Emission Module with a DCLP 505 filter that separates the two fluorophores onto a camera (EVOLVE 512). Fluorescence was measured at 530 ± 15 nm for Venus and at 470 ± 12 nm for CFP emission. Images were acquired by Live Acquisition browser (FEI) and FRET was calculated using Offline Analysis software (FEI). FRET was measured as ratio of CFP over Venus (CFP/Venus ratio). Venus emission was corrected for spillover of CFP emission into the Venus channel (63%). FRET was adjusted for photobleaching and representative experiments were run through a Savitzky–Golay filter for clarity using GraphPad Prism 7 for Windows (GraphPad Software, San Diego, CA).
Stellate neurons were transduced with adenovirus encoding the Yellow PfPKG or cGi-50018 biosensors and imaged 2–3 days later at room temperature under ~2–3 ml/min gravity-driven perfusion with Tyrode’s solution (NaCl 135 mM, KCl 4.5 mM, HEPES 20 mM, Glucose 11 mM, MgCl2 1 mM, CaCl2 2 mM) in a 100 µL chamber. An inverted fluorescent microscope (Nikon, Tokyo, Japan) with a 40x oil objective was used for such imaging. The cells were illuminated at 430 nm by an OptoLED light source (Cairn Research Ltd, Faversham, UK) and the emission was passed through DV2 beam-splitter (Photometrics) with the 05-EM filter set, consisting of a 505DCXR dichroic mirror and specific D480 ± 15 nm (CFP) & D535 ± 20 nm (Venus) emission filters (Chroma Technology Corp.). Images were captured every 15 s by a CoolSNAP HQ2 digital CCD camera (Photometrics) and processed using OptoFluor CoolSNAP software (Cairn Research Ltd.) to record changes in CFP and Venus emission under 430 nm excitation during drug treatment protocols. Changes in the FRET ratio (CFP/Venus) were used as an index of changing cGMP concentration.
Total cGMP measurements
Isolated ventricular cardiomyocytes (cultured for 48 h to ensure similar conditions as cells used for FRET imaging) and HEK293 cells were stimulated in the presence and absence of 50 nM SNAP, 100 µM SNAP and/or 300 nM CNP (as indicated) for 10 min. Cyclic GMP levels were measured using a cGMP enzyme immunoassay kit (Cayman Chemical Company, Ann Arbor, MI, USA) as previously described36.
NO release measurements
Intracellular release of NO was measured by DAF-FM Diacetate (DA), a membrane permeable dye that reacts with NO to form a fluorescent benzotriazole. Cardiomyocytes were plated on laminin-coated cover slides and after 2 h loaded with 20 µM DAF-FM DA in the dark at 37 °C for 30 min. After washing, cover slides were placed into a watertight cell imaging chamber (Attofluor, Thermo Fischer) at room temperature in Buffer B. Cells were visualized through a motorized digital inverted fluorescent microscope (iMIC; FEI, Graefelfing, Germany) with an oil immersion objective (×40 oil 1.35 NA; Olympus, Tokyo, Japan). Cells were excited at 500 ± 10 nm and emission was measured at 530 ± 15 nm.
Statistics and reproducibility
Statistical significance was determined by Two-tailed Student’s t test, Two-tailed Mann–Whitney test, One-way ANOVA with Dunnett’s post hoc test, two-way ANOVA with Sidak's multiple comparisons test and Tukey's multiple comparisons test where indicated using GraphPad Prism 7 and 8 for Windows.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Nucleotide sequence for Yellow PfPKG and Red PfPKG have been deposited in GenBank under the accession numbers MK496217 and MK496218, respectively. The data that support the findings of this study are available from the corresponding author upon request. The authors declare that the data supporting the findings of this study are available within the paper and its supplementary information files.
McMurray, J. J., Packer, M. & Solomon, S. D. Neprilysin inhibition for heart failure. N. Engl. J. Med. 371, 2336–2337 (2014).
Ghofrani, H.-A. et al. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 369, 330–340 (2013).
Lewis, G. D. et al. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis. J. Am. Coll. Cardiol. 47, 1471–1477 (2006).
Lee, D. I. et al. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature 519, 472–476 (2015).
Baliga, R. S. et al. Phosphodiesterase 2 inhibition preferentially promotes NO/guanylyl cyclase/cGMP signaling to reverse the development of heart failure. Proc. Natl Acad. Sci. 115, E7428–E7437 (2018).
Gorshkov, K. & Zhang, J. Visualization of cyclic nucleotide dynamics in neurons. Front. Cell. Neurosci. 8, 395 (2014).
Surdo, N. C. et al. FRET biosensor uncovers cAMP nano-domains at beta-adrenergic targets that dictate precise tuning of cardiac contractility. Nat. Commun. 8, 15031 (2017).
Ponsioen, B. et al. Detecting cAMP-induced Epac activation by fluorescence resonance energy transfer: Epac as a novel cAMP indicator. EMBO Rep. 5, 1176–1180 (2004).
Perera, R. K. et al. Microdomain switch of cGMP-regulated phosphodiesterases leads to ANP-induced augmentation of beta-adrenoceptor-stimulated contractility in early cardiac hypertrophy. Circ. Res. 116, 1304–1311 (2015).
Klarenbeek, J., Goedhart, J., van Batenburg, A., Groenewald, D. & Jalink, K. Fourth-generation epac-based FRET sensors for cAMP feature exceptional brightness, photostability and dynamic range: characterization of dedicated sensors for FLIM, for ratiometry and with high affinity. PLoS ONE 10, e0122513 (2015).
Honda, A. et al. Spatiotemporal dynamics of guanosine 3′,5′-cyclic monophosphate revealed by a genetically encoded, fluorescent indicator. Proc. Natl Acad. Sci. 98, 2437–2442 (2001).
Russwurm, M. et al. Design of fluorescence resonance energy transfer (FRET)-based cGMP indicators: a systematic approach. Biochem. J. 407, 69–77 (2007).
Nikolaev, V. O., Gambaryan, S. & Lohse, M. J. Fluorescent sensors for rapid monitoring of intracellular cGMP. Nat. Methods 3, 23–25 (2006).
Takimoto, E. et al. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ. Res. 96, 100–109 (2005).
Thunemann, M. et al. Transgenic mice for cGMP imaging. Circ. Res. 113, 365–371 (2013).
Norris, R. P. et al. Cyclic GMP from the surrounding somatic cells regulates cyclic AMP and meiosis in the mouse oocyte. Development 136, 1869–1878 (2009).
Gotz, K. R. et al. Transgenic mice for real-time visualization of cGMP in intact adult cardiomyocytes. Circ. Res. 114, 1235–1245 (2014).
Liu, K. et al. Phosphodiesterase 2A as a therapeutic target to restore cardiac neurotransmission during sympathetic hyperactivity. JCI Insight 3 e98694 (2018).
Niino, Y., Hotta, K. & Oka, K. Simultaneous live cell imaging using dual FRET sensors with a single excitation light. PLoS ONE 4, e6036 (2009).
Hopp, C. S., Flueck, C., Solyakov, L., Tobin, A. & Baker, D. A. Spatiotemporal and functional characterisation of the Plasmodium falciparum cGMP-dependent protein kinase. PLoS One 7, e48206 (2012).
McRobert, L. et al. Gametogenesis in malaria parasites is mediated by the cGMP-dependent protein kinase. PLoS Biol. 6, e139 (2008).
Deng, W. & Baker, D. A. A novel cyclic GMP-dependent protein kinase is expressed in the ring stage of the Plasmodium falciparum life cycle. Mol. Microbiol 44, 1141–1151 (2002).
Deng, W., Parbhu-Patel, A., Meyer, D. J. & Baker, D. A. The role of two novel regulatory sites in the activation of the cGMP-dependent protein kinase from Plasmodium falciparum. Biochem. J. 374, 559–565 (2003).
Anamika Srinivasan, N. & Krupa, A. A genomic perspective of protein kinases in Plasmodium falciparum. Protein Struct. Func. Bioinf 58, 180–189 (2005).
Kim, J. J. et al. Crystal structures of the carboxyl cGMP binding domain of the Plasmodium falciparum cGMP-dependent protein kinase reveal a novel capping triad crucial for merozoite egress. PLoS Pathog. 11, e1004639 (2015).
van der Krogt, G. N. M., Ogink, J., Ponsioen, B. & Jalink, K. A comparison of donor–acceptor pairs for genetically encoded FRET sensors: application to the Epac cAMP sensor as an example. PLoS ONE 3, e1916 (2008).
Moltzau, L. R. et al. Different compartmentation of responses to brain natriuretic peptide and C-type natriuretic peptide in failing rat ventricle. J. Pharmacol. Exp. Ther. 350, 681–690 (2014).
Subramanian, H. et al. Distinct submembrane localisation compartmentalises cardiac NPR1 and NPR2 signalling to cGMP. Nat. Commun. 9, 2446 (2018).
Qvigstad, E. et al. Natriuretic peptides increase β1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition. Cardiovasc. Res 85, 763–772 (2010).
Afzal, F. et al. Agents increasing cyclic GMP amplify 5-HT4-elicited positive inotropic response in failing rat cardiac ventricle. Naunyn Schmiedebergs Arch. Pharm. 384, 543–553 (2011).
Andressen, K. W., Norum, J. H., Levy, F. O. & Krobert, K. A. Activation of adenylyl cyclase by endogenous Gs-coupled receptors in human embryonic kidney 293 cells is attenuated by 5-HT7 receptor expression. Mol. Pharmacol. 69, 207–215 (2006).
Flynn, G. E., Black, K. D., Islas, L. D., Sankaran, B. & Zagotta, W. N. Structure and rearrangements in the carboxy-terminal region of SpIH channels. Structure (London, England: 1993) 15, 671–682 (2007).
Lam, A. J. et al. Improving FRET dynamic range with bright green and red fluorescent proteins. Nat. Methods 9, 1005–1012 (2012).
Chu, J. et al. Non-invasive intravital imaging of cellular differentiation with a bright red-excitable fluorescent protein. Nat. Methods 11, 572 (2014).
Filonov, G. S. et al. Bright and stable near-infrared fluorescent protein for in vivo imaging. Nat. Biotechnol. 29, 757 (2011).
Moltzau, L. R. et al. SERCA2 activity is involved in the CNP-mediated functional responses in failing rat myocardium. Br. J. Pharmacol. 170, 366–379 (2013).
Massion, P. B., Feron, O., Dessy, C. & Balligand, J.-L. Nitric oxide and cardiac function: ten Years, Continuing. Circ. Res. 93, 388–398 (2003).
Surdo, N. C. et al. FRET biosensor uncovers cAMP nano-domains at β-adrenergic targets that dictate precise tuning of cardiac contractility. Nat. Commun. 8, 15031 (2017).
Nikolaev, V. O., Bünemann, M., Hein, L., Hannawacker, A. & Lohse, M. J. Novel single chain cAMP sensors for receptor-induced signal propagation. J. Biol. Chem. 279, 37215–37218 (2004).
Song, Q., Saucerman, J. J., Bossuyt, J. & Bers, D. M. Differential integration of Ca2+-calmodulin signal in intact ventricular myocytes at low and high affinity Ca2+-calmodulin targets. J. Biol. Chem. 283, 31531–31540 (2008).
Herring, N. & Paterson, D. J. Neuromodulators of peripheral cardiac sympatho-vagal balance. Exp. Physiol. 94, 46–53 (2009).
Tsutamoto, T. et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96, 509–516 (1997).
Nagai, T. et al. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat. Biotechnol. 20, 87 (2002).
Sharma, R. K. & Wang, J. H. Differential regulation of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isoenzymes by cyclic AMP-dependent protein kinase and calmodulin-dependent phosphatase. Proc. Natl Acad. Sci. USA. 82, 2603–2607 (1985).
Degerman, E., Belfrage, P. & Manganiello, V. C. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J. Biol. Chem. 272, 6823–6826 (1997).
Levy, F. O. Cardiac PDEs and crosstalk between cAMP and cGMP signalling pathways in the regulation of contractility. Naunyn-Schmiedeberg's. Arch. Pharmacol. 386, 665–670 (2013).
Harada, K. et al. Red fluorescent protein-based cAMP indicator applicable to optogenetics and in vivo imaging. Sci. Rep. 7, 7351 (2017).
Zapata-Hommer, O. & Griesbeck, O. Efficiently folding and circularly permuted variants of the Sapphire mutant of GFP. BMC Biotechnol. 3, 5 (2003).
Campbell, R. E. et al. A monomeric red fluorescent protein. Proc. Natl Acad. Sci. USA. 99, 7877–7882 (2002).
Orstavik, O. et al. The inotropic effect of the active metabolite of levosimendan, OR-1896, is mediated through inhibition of PDE3 in rat ventricular myocardium. PLoS ONE 10, e0115547 (2015).
Meier, S. et al. PDE3 inhibition by C-type natriuretic peptide-induced cGMP enhances cAMP-mediated signaling in both non-failing and failing hearts. Eur. J. Pharmacol. 812, 174–183 (2017).
The authors thank Iwona Gutowska-Schiander for technical assistance. This work was supported by the South-Eastern Norway Regional Health Authority, the Norwegian Council on Cardiovascular Diseases, The Research Council of Norway, Stiftelsen Kristian Gerhard Jebsen, The Anders Jahre Foundation for the Promotion of Science, The Simon Fougner Hartmann Family Foundation, The Family Blix Foundation and grants from the University of Oslo. C.K. is funded by the NIH grant R01 GM090161.
The authors have no competing interests to declare.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Calamera, G., Li, D., Ulsund, A.H. et al. FRET-based cyclic GMP biosensors measure low cGMP concentrations in cardiomyocytes and neurons. Commun Biol 2, 394 (2019). https://doi.org/10.1038/s42003-019-0641-x
Naunyn-Schmiedeberg's Archives of Pharmacology (2020)